Rheumatoid Arthritis: Early Diagnosis, Medication & Treatment Management

At a glance

Affected in Germany~550,000 adults (DGRh); women affected ~3× more often
Age of onsetUsually middle adulthood; possible at any age in principle
CauseAutoimmune disease — the immune system attacks the joint lining (synovium)
Treatment goalRemission (treat-to-target) — the earlier treatment starts, the better the long-term prognosis
Medication (selection)Methotrexate as base therapy, DMARDs, biologics, JAK inhibitors, biosimilars
ICD-10M05 (seropositive), M06 (seronegative)

Table of contents

  1. What is rheumatoid arthritis?
  2. Symptoms — early detection saves joints
  3. Causes and risk factors
  4. Diagnosis: Why see a rheumatologist quickly?
  5. Medication: Step therapy & treat-to-target
  6. Non-drug treatment
  7. Fatigue and psychological burden
  8. Everyday life with rheumatism
  9. How brite helps you
  10. FAQ
  11. Related topics

1. What is rheumatoid arthritis?

Rheumatoid arthritis (RA) is a chronic autoimmune disease in which the immune system mistakenly attacks the joint lining (synovium). The result is inflammation, swelling and pain — and without treatment, progressive joint damage can occur.

Unlike osteoarthritis — which is more akin to joint wear — RA is an inflammatory systemic disease. It can also affect structures outside the joints (lungs, heart, eyes, blood vessels). Typical features are a relapsing course and a usually symmetrical involvement of the small joints of the hands and feet.¹

Window of opportunity — the first months are decisive With early diagnosis and modern medications (biologics, JAK inhibitors), remission can be achieved in a relevant proportion of those affected. The earlier targeted therapy begins, the better the long-term prognosis usually is.¹˒²

2. Symptoms — early detection saves joints

Early symptoms — do not ignore

  • Morning joint stiffness lasting a markedly prolonged time — an important early sign and a clue distinguishing RA from osteoarthritis
  • Swelling and warmth of small joints — typically the finger base and middle joints, the toe base joints and the wrists
  • Symmetrical involvement — the same joints affected on both sides
  • Joint pain — often worst at night and in the morning, improving with movement
  • Pain when squeezing the finger base joints sideways (Gaenslen's sign)
  • Fatigue — pronounced exhaustion, experienced by many as particularly burdensome
  • Flu-like feeling of illness, slightly raised temperature
  • Occasionally: carpal tunnel syndrome as the first sign of RA

Late symptoms (without adequate treatment)

  • Joint deformities (e.g. ulnar deviation of the fingers, swan-neck or boutonnière deformity)
  • Rheumatoid nodules — firm nodules under the skin (elbows, fingers, heel)
  • Involvement of other organs (interstitial lung disease, inflammation of the pericardium, eye inflammation)
  • Increased cardiovascular risk — RA is considered an independent cardiovascular risk factor
With swelling + morning stiffness for several weeks: see a rheumatologist promptly Every week without targeted therapy can potentially contribute to lasting joint damage. The first months after symptom onset often determine the long-term prognosis.¹

3. Causes and risk factors

  • Genetic predisposition: Certain HLA genes (including HLA-DR4) are the most important genetic risk factors — but not everyone with them develops the disease
  • Smoking: The most important modifiable risk factor. It can markedly increase the risk of RA and worsen the response to methotrexate and biologics. Quitting smoking can support treatment.¹˒³
  • Sex: Women are affected about three times more often than men
  • Periodontitis: Evidence of a link with the development of RA
  • Overweight: Can increase the risk of disease and impair treatment response
  • Autoantibodies (rheumatoid factor, anti-CCP) can be detectable years before the first symptoms

4. Diagnosis: Why see a rheumatologist quickly?

In RA, an early diagnosis is considered the key to the further course. The goal is usually to start treatment within a few months of symptom onset. The ACR/EULAR criteria are often used for classification.¹˒²

Laboratory tests

  • CRP and ESR (inflammatory markers): Often elevated in active RA. Important: normal values do not rule out RA.
  • Anti-CCP antibodies: An important serological marker with high specificity. Can be positive years before the first symptoms — and also has prognostic significance.
  • Rheumatoid factor (RF): Positive in a large proportion of RA patients, but less specific than anti-CCP. Seropositive = RF and/or anti-CCP detectable.
  • Blood count: Often anaemia of chronic disease; raised platelets possible.

Imaging

Joint ultrasound (arthrosonography) — standard in practice
Can make synovitis and small joint effusions visible early — often before clear swelling is clinically apparent. Quick, with no radiation exposure.
MRI — particularly sensitive for early erosions
Particularly sensitive for early erosions and bone marrow oedema — changes that are often not yet visible on X-ray. Usually used in unclear cases.
X-ray (hands and feet)
Usually shows changes only in later stages. Important as a baseline finding and for follow-up.

More: Preparing for a doctor's appointment.

5. Medication: Step therapy and treat-to-target

Drug treatment today usually follows the principle of "treat-to-target" (T2T): the goal is remission or at least low disease activity — with regular monitoring and adjustments until the target is reached.¹

Step 1 Conventional synthetic DMARDs (csDMARDs)
Methotrexate (MTX) — base therapy of RA
The gold standard of base therapy for many years.
Dosing: Only once a week (not daily!) — as a tablet or subcutaneous injection
Folic acid: Usually prescribed according to an individually defined schedule — markedly reduces side effects
Onset of action: Usually after a few weeks
Side effects: Nausea, mouth lining inflammation, changes in liver values — regular blood tests are standard
⚠ No alcohol while on MTX (liver toxicity)
⚠ Strictly contraindicated if planning pregnancy and during pregnancy — always clarify the details with the rheumatology team¹
Leflunomide
An alternative if MTX is not tolerated. Regular lab monitoring recommended. It usually has a long residence time in the body — relevant when changing therapy.
Sulfasalazine and hydroxychloroquine
Further conventional agents — either in combination with MTX or as an alternative. Regular eye examinations are usually recommended while on hydroxychloroquine.
Step 2 Biologics and JAK inhibitors — when the response is insufficient

If a conventional base therapy does not reach the treatment goal after a few months, current guidelines often add targeted therapies (usually in addition to MTX). Biologics and JAK inhibitors are considered equivalent options.¹

Biologics (bDMARDs)

TNF-alpha blockers
Agents: Adalimumab, etanercept, infliximab, certolizumab, golimumab
Block the inflammatory messenger TNF-alpha. Given as an injection at certain intervals or as an infusion. Biosimilars are available for several of these agents.
IL-6 receptor antagonists
Agents: Tocilizumab, sarilumab
A good option with strongly elevated CRP and pronounced systemic inflammation. Tocilizumab is also approved as monotherapy without MTX — a possible advantage if MTX is not tolerated.
Further biologics
Abatacept (T-cell co-stimulation modulator) — a further mechanism of action, favourable safety profile.
Rituximab (B-cell depletion) — typically when the response to other biologics is insufficient; given as an infusion in certain cycles.

JAK inhibitors (tsDMARDs)

JAK inhibitors — as tablets
Intervene in intracellular signalling pathways of inflammation. Possible advantage: taken as a tablet instead of injection/infusion; comparatively rapid onset of action.
Agents available in Germany: Tofacitinib, baricitinib, upadacitinib, filgotinib
Before starting therapy and during the course: regular lab monitoring needed (blood count, liver values, thromboembolism risk).¹
Safety note on JAK inhibitors (ORAL Surveillance study) The ORAL Surveillance study found, in patients with certain cardiovascular risk factors on tofacitinib, signs of an increased risk of thromboembolism and certain cancers. EULAR and German specialist societies therefore recommend preferring biologics over JAK inhibitors in at-risk patients (older age, cardiovascular risk factors). The individual decision is always made by the rheumatology team.⁶

Biosimilars

Biosimilars are biotechnologically produced follow-on products of biologics with comparable efficacy and a comparable safety profile. A switch is generally considered safe according to the guideline and can help reduce treatment costs. More: Generics vs. originals.¹

Adjunctive therapy

Cortisone (glucocorticoids) — only short-term as a bridge
Usually given at a low dose and only for short-term bridging until a DMARD therapy has its full effect. Long-term high-dose cortisone therapy should usually be avoided according to current guidelines. More: Tapering off cortisone.
NSAIDs (e.g. ibuprofen, diclofenac) — only as a bridge
Can help relieve pain but have no disease-modifying effect. Only as a bridge and as needed; with longer use, gastric protection is often advisable. More: Stomach problems from medication.
Never stop DMARDs, biologics or JAK inhibitors on your own A relapse can damage the joints quickly and sometimes permanently. Always discuss changes with the rheumatology team. More: Stopping medication, Check interactions.

6. Non-drug treatment

  • Physiotherapy: A central element — preserving joint function, relieving pain, strengthening muscles. During acute flares, adapted, pain-oriented movement instead of strict rest.
  • Occupational therapy: Joint protection training, assistive devices (e.g. thickened grips), splints. Aim: to make everyday tasks easier.
  • Movement and sport: Joint-friendly activities (swimming, cycling, yoga, moderate strength training) are considered an important building block of treatment and can have a positive effect on fatigue.
  • Nutrition: A Mediterranean-style, anti-inflammatory diet (vegetables, fruit, olive oil, nuts, fish with omega-3) can sensibly complement treatment — but does not replace drug therapy.
  • Quitting smoking: One of the most important non-drug measures. Smoking worsens the course and the response to medication.¹

7. Fatigue and psychological burden

Fatigue — a pathological exhaustion — is common in RA and is experienced by many as a particularly burdensome symptom. It cannot simply be "rested away" with sleep and differs markedly from normal tiredness.¹˒³

Depression and anxiety occur more often in people with RA than in the general population. What helps according to current evidence: regular physical activity (with one of the strongest effects against fatigue), sleep hygiene, targeted stress management, pacing (consciously budgeting one's energy) and, if needed, psychological support. Fatigue is a real symptom of the disease — the topic should be actively discussed with the rheumatology team.

8. Everyday life with rheumatism

  • Work: Most occupations are possible with well-controlled RA. Ergonomic adjustments can be helpful. With a recognised degree of disability, special employment-law arrangements may apply under certain circumstances (in Germany, via the Integration Office).
  • Flares: Cooling, pain-oriented movement and early consultation with the rheumatology team are sensible.
  • Vaccinations: Under immunosuppressive therapy, certain vaccinations are especially important. Live vaccines are usually not recommended under immunosuppression. Have the vaccination status checked and completed before starting therapy.
  • Cardiovascular risk: RA is considered an independent cardiovascular risk factor. Regular monitoring of blood pressure, blood lipids and blood sugar is sensible. Effective RA therapy can also influence the cardiovascular risk.¹
  • Alcohol: While on methotrexate, particular restraint is usually advisable (liver toxicity). More: Medication and alcohol.

How brite helps you with rheumatism

Methotrexate once a week, folic acid the next day, the biologic injection at fixed intervals — brite keeps track of everything.

  • Intake reminder — methotrexate once a week, folic acid the next day, the biologic injection at fixed intervals, JAK inhibitors daily: brite reminds you reliably. Set up a reminder
  • Interaction check — check MTX, biologics and JAK inhibitors in combination with other medications or vaccinations for free. Check now
  • Health record — document flares, joint pain, morning stiffness, fatigue and blood values in a structured way. Track your record
  • Digital medication plan — all medications clearly laid out for the rheumatology team, GP and pharmacy. Go to the medication plan
Start now for free
brite app

FAQ: Common questions about rheumatism

In the classic sense, rheumatoid arthritis is not curable. With modern, early therapy, remission or at least low disease activity can be achieved in a relevant proportion of those affected. The decisive factors are early diagnosis and consistent treat-to-target.¹
RA is an autoimmune disease with inflammation that mainly affects the small joints symmetrically and causes longer-lasting morning stiffness. Osteoarthritis, by contrast, is joint wear that mainly affects load-bearing joints (knees, hips); the morning stiffness is usually much shorter, and systemic inflammation is typically absent.
At the lower dose usually used in RA, methotrexate has been established and well studied for decades. Important safety aspects: take it only once a week (not daily!), accompanying folic acid as directed by the doctor, regular lab monitoring and strict abstinence from alcohol. MTX is strictly contraindicated in pregnancy and when planning a pregnancy.¹
Biologics are biotechnologically produced antibodies that can specifically block inflammatory messengers (e.g. TNF-alpha or IL-6). They are usually used when base therapy with MTX is not sufficient. Biosimilars are follow-on products of existing biologics with comparable efficacy and safety. A switch is generally considered safe according to the current guideline.¹
According to the current guideline, both groups are considered equally effective in many situations. JAK inhibitors are taken as tablets and often have a rapid onset of action. In at-risk patients (older age, cardiovascular risk factors), a biologic is usually preferred according to the ORAL Surveillance study. The individual decision is always made by the rheumatology team.¹˒⁶
Yes — movement is considered one of the most important building blocks of treatment in RA and has, among other things, good evidence regarding fatigue. Joint-friendly activities such as swimming, cycling, yoga or moderate strength training are recommended. During acute flares the activity level is adjusted, but usually not paused entirely.
Fatigue is a pathological exhaustion that cannot simply be slept off. It is partly immunologically driven. What usually helps: regular movement (best evidence), pacing (consciously budgeting one's energy), good sleep hygiene, stress management and, if needed, psychological support — and an open conversation with the rheumatology team.
Smoking can markedly increase the risk of RA, worsen the course and reduce the response to methotrexate and biologics. In addition, smoking raises the already increased cardiovascular risk. Quitting smoking is therefore considered one of the most effective single non-drug measures.¹˒³
With sustained remission, a stepwise reduction of therapy may be considered — usually starting with cortisone, then possibly with biologics or JAK inhibitors (e.g. by lengthening the intervals or reducing the dose). Methotrexate is usually kept on if possible. Completely stopping all DMARDs carries a relevant risk of relapse and should only be considered under close rheumatological monitoring.¹

11. Related topics

Tapering off cortisone Generics vs. originals (biosimilars) Medication and alcohol Stomach problems from medication Interactions between medications Stopping medication Side effects of medication

Sources

  1. S3 guideline "Drug therapy of rheumatoid arthritis" (DGRh et al., AWMF Reg. No. 060-004, version 3.0, January 2026). awmf.org
  2. EULAR Recommendations for the management of rheumatoid arthritis (2022 Update). ard.bmj.com
  3. German Rheumatism League (Deutsche Rheuma-Liga): Rheumatoid arthritis — patient information and guides. rheuma-liga.de
  4. German Society for Rheumatology and Clinical Immunology (DGRh). dgrh.de
  5. gesundheitsinformation.de (IQWiG): Rheumatoid arthritis. gesundheitsinformation.de
  6. Ytterberg S. R. et al.: Cardiovascular and Cancer Risk with Tofacitinib in Rheumatoid Arthritis (ORAL Surveillance), NEJM 2022. pubmed.ncbi.nlm.nih.gov
Medical disclaimer: This article is for general information and does not replace medical advice, diagnosis or treatment. The choice of medication and dosages are always determined individually by the treating doctor — usually in close coordination with a rheumatology practice or clinic. New joint swelling with morning stiffness lasting several weeks should be assessed promptly by a rheumatologist. DMARDs, biologics and JAK inhibitors must not be stopped on one's own. Last updated: April 2026.